Last updated on September 2017

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis


Brief description of study

This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are insufficiently responding to their stable dose of methotrexate treatment.

Clinical Study Identifier: NCT02831855

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

NZOZ Lecznica MAK-MED. S.C.
Nadarzyn, Poland
7.3miles
  Connect »